HomeAI · summaries
Storia in 2 fonti
Roche's ctDNA-guided approach in post-surgical bladder cancer pays off with Tecentriq nod
With the help of DNA testing company Natera and its personalized molecular residual disease (MRD) blood test Signatera, Roche’s PD-L1 inhibitor Tecentriq has chalked up its eleventh U.S. | The FDA approved the Tecentriq label expansion alongside Natera's Signatera as a companion diagnostic.
Confronto fonti
2 prospettive sulla stessa storiaTimeline cronologica
- ·
healio.com
Tecentriq lands FDA approval as adjuvant treatment for muscle invasive bladder cancer
The FDA has approved atezolizumab and atezolizumab with hyaluronidase-tqjs as adjuvant treatment for certain adults with muscle invasive bladder cancer. Atezolizumab…
- ·
fiercepharma.com
Roche's ctDNA-guided approach in post-surgical bladder cancer pays off with Tecentriq nod
With the help of DNA testing company Natera and its personalized molecular residual disease (MRD) blood test Signatera, Roche’s PD-L1 inhibitor Tecentriq has chalked up its…
